Global Osteoarthritic Pain Management Treatment Market, By Type (Hip Osteoarthritis, Spinal Osteoarthritis), Drug (NSAIDs, Corticosteroids, Hyaluronic acid Injection, Other Drugs), Diagnosis (Imaging, Joint Fluid Analysis), Treatment (Medication, Surgery, Therapy), End Users (Hospitals, Medical Institutes), – Industry Trends and Forecast to 2029
Market Analysis and Size
Joint pain is common in people of all ages and is related to the bone structure of the knee. Joint pain is caused by certain injuries or the progression of a chronic medical condition. Knee pain worsens with age. pain in young people is associated with overuse of joints as a result of physical activity or sports. It is caused in the elderly by the wear and tear of the joint as a result of osteoarthritis and rheumatoid arthritis. Damaged menisci, tendinitis, pseudo gout, bursitis, obesity, and other factors can all contribute to joint pain. According to the Centres for Disease Control and Prevention, arthritis, a leading cause of knee pain, affects 54.4 million adults in the United States.
Data Bridge Market Research analyses that the osteoarthritic pain management treatment market is expected to reach the value of USD 15.34 billion by the year 2029, at a CAGR of 7.25% during the forecast period. The significant increase in the adoption of pain medications and growing awareness by government is a critical factor driving market growth.
Market Definition
Osteoarthritis is a type of joint disorder that attacks the cartilage between the bones, causing the joints to swell and turn red, making it difficult for the joints to move properly. Swelling, decreased range of motion and immobility in the arms and legs are common symptoms, especially when the spine is affected by osteoarthritis.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Hip Osteoarthritis, Spinal Osteoarthritis), Drug (NSAIDs, Corticosteroids, Hyaluronic acid Injection, Other Drugs), Diagnosis (Imaging, Joint Fluid Analysis), Treatment (Medication, Surgery, Therapy), End Users (Hospitals, Medical Institutes)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India),
|
|
Opportunities
|
|
Osteoarthritic Pain Management Treatment Market Dynamics
Drivers
- The rise in the awareness by government
Increased government awareness programmes about the disease will boost market growth, as will an increase in the prevalence of osteoarthritis, an increase in the population susceptible to osteoarthritis, an increase in healthcare affordability in the US, and an increase in people's knowledge and awareness, among other factors driving the osteoarthritic pain management treatment market growth.
- The increase in the personalised medicines and collaborations from market players
The rise in personalised medicines for osteoarthritis, as well as the rise in product development collaborations, will create new opportunities for the osteoarthritic pain management treatment market during the forecast period.
Regulatory Compliance
Maintaining compliance with medical reforms and regulations raises the demand for these solutions.
- Government investments for healthcare interoperability
The increase in the funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the osteoarthritic pain management treatment market.
.Restraints/Challenges
The increases in the risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, as well as the increased commercialization of alternatives, are the major factors acting as restraints, and will further challenge the osteoarthritic pain management treatment market during the forecast period.
This osteoarthritic pain management treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteoarthritic pain management treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Osteoarthritic Pain Management Treatment Market
In the best-case scenario, the COVID-19 pandemic has had a significant long-term positive impact on the osteoarthritic pain management treatment market. Initially, there was a drop in the market in early 2020 as a result of lockdowns and quarantine measures. However, as the disease spread around the world, the number of laboratories, COVID-19 testing sites, and processing facilities handling SARS-CoV-2 samples, reagents, and vaccines increased expon The COVID-19 outbreak is expected to have a minor impact on the market for osteoarthritis therapeutics. Corticosteroids are one of the drugs that have seen a decrease in use. Although there is no evidence that corticosteroid injections significantly increase the risk of infection, there may be a reduction in immune response for a few weeks after the procedure. While the risk is extremely low, it must be considered when deciding whether or not to proceed with the procedure. It should also be noted that the WHO suggested avoiding systemic corticosteroids in one of its guidelines for the management of severe acute respiratory infection in patients with coronavirus.entially.
.Recent Development
- Voltaren was introduced in the United States by GlaxoSmithKline Plc (UK) in 2020.
- Horizon Therapeutics Plc (Ireland) expanded its presence in the United States in 2020.
- Kitov Pharma Ltd. (Israel) signed an agreement with Coeptis Pharmaceuticals in 2019, which aided in the efficient distribution and commercialization of Consensi.
- Atnahs opened a sales office in Dubai, UAE, in 2018.
- Flexion Therapeutics, Inc. (US) received FDA approval for ZILRETTA in 2017.
Global Osteoarthritic Pain Management Treatment Market Scope
The osteoarthritic pain management treatment market is segmented on the basis type, drug, diagnosis, treatment and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Hip osteoarthritis
- Spinal osteoarthritis.
On the basis of type, the osteoarthritic pain management treatment market is segmented into hip osteoarthritis and spinal osteoarthritis.
Drug
- NSAIDs
- Corticosteroids
- Hyaluronic acid injection
- Other drugs
Based on drug, the osteoarthritic pain management treatment market is segmented into NSAIDs, corticosteroids, hyaluronic acid injection and other drugs.
Diagnosis
- Imaging
- Joint fluid analysis
Based on diagnosis, the osteoarthritic pain management treatment market is segmented into imaging and joint fluid analysis.
Treatment
- Medication
- Surgery
- therapy
Based on treatment, the osteoarthritic pain management treatment market is segmented into medication, surgery and therapy.
Distribution channel
- Hospitals
- Medical institutes
Osteoarthritic pain management treatment is also segmented on the basis of distribution channel into hospitals and medical institutes.
Osteoarthritic Pain Management Treatment Market Regional Analysis/Insights
The osteoarthritic pain management treatment market is analysed and market size insights and trends are provided by country, type, drug, diagnosis, treatment and end-users as referenced above.
The countries covered in the osteoarthritic pain management treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the osteoarthritic pain management treatment market due to changing lifestyles and rising healthcare costs. a rise in research funding availability, a large patient population, rising healthcare expenditures, a well-developed healthcare sector, and government support for R&D in this region Asia-Pacific is expected to be the fastest growing region in terms of osteoarthritic pain management treatment due to the large patient population and the presence of a large market opportunity.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The osteoarthritic pain management treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for osteoarthritic pain management treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the osteoarthritic pain management treatment market. The data is available for historic period 2010-2020.
Competitive Landscape and Osteoarthritic Pain Management Treatment Market Share Analysis
The osteoarthritic pain management treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteoarthritic pain management treatment market.
Some of the major players operating in the osteoarthritic pain management treatment market are
- Sanofi (France)
- Horizon Therapeutics PLC (Ireland)
- Johnson & Johnson (US)
- GlaxoSmithKline PLC (UK),
- Bayer AG (Germany)
- Abbott (US)
- Pfizer, Inc. (US)
- Eli Lilly (US)
- Anika Therapeutics, Inc (US)
- Novartis AG (Switzerland)
- Ferring Pharmaceuticals (Switzerland)
- Bioventus (US)
- Zimmer Biomet Holdings, Inc. (US)
- Fidia Farmaceutici s.p.a. (Italy)
- Flexion Therapeutics, Inc. (US)
- Pharmed Limited (India)
- Virchow Biotech (India),
SKU-